Canaccord Raises Price Target for Biodesix (BDSX) Due to Higher Revenue Assumptions
On May 5, Canaccord upgraded its price target on Biodesix from $20 to $22 while maintaining a 'Buy' rating. The adjustment was driven by higher revenue assumptions and improved operating margins in the firm's DCF model.
